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Universiteit Antwerpen, Edegem, Belgium
OBJECTIVES: To study the prevalence of renal failure in
a large sample of type 2 diabetes patients in Belgium and
to compare the results with the data of the Belgian ESRD
registry. METHODS: A total of 5355 patients, 2530
males and 2825 females, suffering from type 2 diabetes
and treated with oral antidiabetic drugs were recruited
from the patient ﬁles of 345 Belgian general practition-
ers. Age, gender, body height, body weight, and serum
creatinine were recorded. Renal function was calculated
using a BMI-corrected Cockroft-Gault formula and the
abbreviated MDRD formula. Annual incidence of dia-
betics starting renal replacement therapy was retrieved
from the Belgian national ESRD registry and diabetes
prevalence data from the Scientiﬁc Institute of Public
Health. RESULTS: The mean age was 68 years in females
and 64 years in males. The mean body weight was 76.01
kg in females and 84.64kg in males. The mean serum cre-
atinine was 1.04mg/dl (range: 0.5–3.0mg/dl) in females
and 1.14mg/dl (range: 0.5–10.2mg/dl) in males. Serum
creatinine levels had a tendency to rise, both in females
and males, from the age of 60 years. Renal function
showed a tendency to decrease with age, regardless of the
method of calculation. If we compare these results with
those found in a Belgian study of the general population,
we observed that the 3rd percentile of the renal function
estimate in diabetics was almost identical to that of 
the general population. The annual incidence of ESRD
among diabetics type 2 is 23 per million inhabitants.
Given a prevalence of diabetes of 2.6%, the annual inci-
dence of ESRD can be calculated as 0.088%. CONCLU-
SIONS: Apparently, there is no excess renal failure in the
diabetes population and the decrease in renal function
with advancing age is identical in both populations.
ESRD among diabetics type 2 is rare.
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OBJECTIVES: Diabetes Mellitus (DM) is a major health
care issue potentially causing prolonged ill health and pre-
mature death. Good adherence to prescribed diabetic
regimen is important to prevent complications but it
needs supports from a variety of health care profession-
als. This study was to explore the non-compliance proﬁle
of diabetic patients and to evaluate the clinical beneﬁts
by a pharmacist-managed diabetes clinic on the degree of
glycemic control through the provision of diabetic infor-
mation and the implementation of a drug compliance
enhancement program for the non-compliant diabetic
patients. METHODS: Patients with poor medication
compliance were recruited to receive three counseling 
sessions carried out by a hospital pharmacist. The base-
line levels of compliance and hemoglobin A1C (HbA1C)
were documented. The responsibility of the pharmacist 
in the clinic was to educate all patients individually
regarding diabetes and its complications and on the
proper use of their medicines. Patients were reassessed
and reinforced on their levels of compliance and medica-
tion knowledge during the subsequent visits. The primary
outcome measurement was the change in HbA1C over 
the 12-month study period. RESULTS: Ninety-ﬁve
patients were recruited during the 12-month study period
with 91 patients completed the study. Improvement of
HbA1C was observed as compared with the ﬁrst clinic
visit to the ﬁnal clinic visit (7.43, b 1.57% to 7.15, b
1.33%, p < 0.005). The mean compliance level improved
signiﬁcantly from 41.3% to 97.8% (p < 0.005). CON-
CLUSION: The study suggested that pharmacist-
managed compliance clinic for non-compliant diabetic
patients was effective and had a clinical impact on the
glycemic control of patients. Pharmacist can play an
important role in implementing and monitoring diabetic
therapy along with the multidisciplinary team effort in
diabetes management.
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OBJECTIVES: The objectives were to assess whether
rapid transitioning in newly diagnosed type II diabetics
from diet and exercise to insulin results in better blood
glucose control as measured by HbA1C and reduced dia-
betes-related complications. METHOD: We used longi-
tudinal data from IMS Mediplus-Germany for newly
diagnosed type II diabetics between June 1993 and May
2001 with at least two HbA1C readings. Patients with
complications at baseline were excluded. Treatment was
categorized as diet and exercise, sulfonylureas, antihy-
perglycemic drug combinations, insulin or insulin plus
another agent. Modiﬁcations to treatment were tracked
and rapid use of insulin was either initial insulin use or
immediate change from diet and exercise to insulin. Area
under the curve (AUC) for HbA1C was calculated and
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divided by the duration of time in the data. A regression
model explained AUC as a function of rapid transition-
ing to insulin. A Cox model assessed the relationship
between the time to ﬁrst complication and AUC, rapid
transition to insulin and the number of modiﬁcations.
RESULTS: A total of 3137 patients satisﬁed all study
entry criteria; 1230 patients were initiated on diet and
exercise, 1756 on oral agents, and 151 on insulin. Demo-
graphics were comparable. Of patients initiated on diet
and exercise 66 switched to insulin in 2.4 months. In the
linear regression model explaining AUC (R2 = 0.185),
rapid transition to insulin was signiﬁcant (-0.19, p =
0.04) indicating that insulin sooner improves blood
glucose control. Of the 3137 patients, 954 encountered
complications. Time to ﬁrst complication was negatively
related to AUC (-0.04, p < 0.01) and rapid use of insulin
(-0.45, p < 0.01) with hazard ratios of 0.962 and 0.637
and positively related to the number of modiﬁcations
(0.08, p < 0.01) with a hazard ratio of 1.083. CON-
CLUSIONS: Initial or immediate transition to insulin
results in better blood glucose control that reduces the
onset of diabetes-related complications.
DIABETES—Cost Studies
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OBJECTIVES: Pioglitazone (PIO), a thiazolidinedione, is
a member of a new class of oral antidiabetic agents 
targeted to treat insulin resistance, the major underlying
cause of type 2 diabetes mellitus. Insulin (INS) is believed
to be the “gold standard” for achieving optimal glycaemic
control. This study is aimed to compare both treatment
options with regard to metabolic control and effective-
ness under the conditions of daily practice. METHODS:
Prospective, controlled, non-randomized observational
study where patient selection, allocation to treatment and
dose was left at the physicians’ discretion. Quality stan-
dards included a central laboratory and a regular moni-
toring. Primary parameter was the change of HbA1C
compared to baseline (D HbA1C) where a difference of
<0.5% between both arms was set for deﬁning non-
inferiority. Analyses were performed under the perspec-
tive of the German Statutory Health Care System.
RESULTS: A total of 299 and 218 patients in whom PIO
or INS was started for insufﬁcient metabolic control were
treated for a mean duration of 26 weeks at 51 specialised
out-patient diabetic centres. Adjusted D HbA1C (-0.72),
PIO; (-0.42) INS) and adjusted D Fasting Plasma Glucose
-24.5mg/dl, PIO; -19.5mg/dl, INS) were observed.
Responder rates (adjusted D HbA1C ≥0.6%) were 54.9%
(PIO) and 37.2% (INS), respectively. Mean total treat-
ment costs were €1207 (PIO) and €1510 (INS) where
mean costs for antidiabetic medication and glucose self-
monitoring (dip-stick measurement) could be assessed as
€646 (PIO) and €774 (INS). Compared to INS, PIO
revealed to be more cost-effective (D HbA1C/€1000) in
the insulin resistant (ATP-III), younger (<64 years) and
more obese (BMI <30kg/m2) individuals with shorter
diabetes duration (<5 years). For INS a similar trend
could not be observed. CONCLUSIONS: PIO proved to
be non-inferior to INS treatment in terms of metabolic
control as well as cost-effectiveness. Targeting individual
patient proﬁles achieve best possible outcomes.
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OBJECTIVES: To compare pharmacy costs for patients
fulﬁlling HEDIS® for diabetes in an HMO disease man-
agement program (DDM) vs. those not in the program.
METHODS: We analyzed HMO paid drug costs among
1362 continuously enrolled GHP members with pre-
scription coverage who met HEDIS® criteria for diabetes
January 1, 2000 to December 31, 2001. We compared
patients in an opt-in “DDM” versus those not enrolled.
Multiple linear regression was used to control for the
impact of age and gender. RESULTS: Of 1362 patients
fulﬁlling criteria, 1273 (93.5%) were in DDM versus 
89 (6.5%) not in DDM. The DDM male/female ratio
(Program M/F = 52.4%/47.6% vs. Non-program M/F =
58.6%/41.4.1%, p = 0.07) was similar and those in DDM
were 1.9 years younger than non-DDM (56.0 vs. 57.9
years, p = 0.15). Mean pharmacy PMPM paid claims for
DDM vs. non-DDM patients was $92.24 ( STD = $99.18)
vs $143.98 (STD = $136.78), (t = 4.63, p < .0001). The
mean PMPM for DDM vs. non-DDM for insulin for
($20.17 Program vs. $15.49), other diabetes medications
($29.71 vs. $25.39) and diabetes supplies ($4.31 vs.
$5.77) were not statistically different. The mean PMPM
for non-diabetes medications for DDM patients was 
of $61.06 (STD = $81.91) vs, a mean PMPM of $123.34
(STD = $131.97). After controlling for age and gender,
this difference was statistically signiﬁcant (p < .0001).
CONCLUSIONS: We observed lower pharmacy costs for
non-diabetes medicines among DDM participants. These
data suggest that diabetes disease management is not nec-
essarily associated with an increase in pharmacy costs.
